Role of glipizide therapy on oxidative stress parameters in the patient with Type-II diabetes mellitus
Keywords:
Type-II diabetes mellitus, Oxidative stress, Reactive oxygen species, GlipizideAbstract
Background: Oxidative stress has an important role in the pathophysiology of diabetes mellitus (DM) Type-II. Oxidative stress has an important role in the progression of DM Type-II and its related complications such as retinopathy, neuropathy and many others. The present study was carried out to evaluate the effect of glipizide therapy on oxidative stress parameters in Type-II DM.
Methods: Thirty newly diagnosed diabetes patients were given glipizide therapy on 1st day and continue for 3 months. 30 non-diabetic healthy volunteers served as a control. Plasma malondialdehyde (MDA), superoxide dismutase (SOD) and catalase levels were measured at the time of enrollment and at the end of 3 months of glipizide treatment.
Result: Theresults are analyzed using paired t-test. Plasma MDA was significantly increased, whereas SOD and catalase were significantly reduced in newly diagnosed diabetic patients as compared to control. After 3 months of glipizide therapy, plasma MDA was significantly reduced, whereas SOD and catalase were significantly increased.
Conclusion: Glipizide therapy significantly reduced oxidative free radicals and increased antioxidant mechanism, which reduced oxidative stress, progression DM-II and its related complication.
Metrics
References
American Diabetes Association. Standards of medical care in diabetes – 2010. Diabetes Care. 2010;33 Suppl 1:S11-61.
Seidell JC, Björntorp P, Sjöström L, Sannerstedt R, Krotkiewski M, Kvist H. Regional distribution of muscle and fat mass in men – new insight into the risk of abdominal obesity using computed tomography. Int J Obes. 1989;13(3):289-303.
DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88(4):787-835, ix.
Brunton L, Lazo J, Parker K. Goodman & Gilman’s the Pharmacological Basis of Therapeutics. New York: McGraw-Hill Education; 2005.
Gupta RK, Rehan HS, Rohatagi A, Bhatacharjee J, Chopra D. The effect of glipizide, metformin and rosiglitazone on nontraditional cardiovascular risk factors in newly diagnosed patients with type 2 diabetes mellitus. Int J Diabetes Dev Ctries. 2010;30(3):123-7.
Grodsky GM, Anderson CE, Coleman DL, Craighead JE, Gerritsen GC, Hansen CT, et al. Metabolic and underlying causes of diabetes mellitus. Diabetes. 1982;31 Suppl 1:45 53.
Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med. 1996;20(3):463 6.
Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem. 2004;279(41):42351-4.
West IC. Radicals and oxidative stress in diabetes. Diabet Med. 2000;17(3):171-80.
Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol. 2006;212(2):167-78.
Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48(1):1-9.
Matteucci E, Giampietro O. Oxidative stress in families of type 1 diabetic patients. Diabetes Care. 2000;23(8):1182-6.
Noda Y, Mori A, Packer L. Gliclazide scavenges hydroxyl, superoxide and nitric oxide radicals: an ESR study. Res Commun Mol Pathol Pharmacol. 1997;96(2):115-24.
Renier G, Desfaits AC, Serri O. Gliclazide decreases low density lipoprotein oxidation and monocyte adhesion to the endothelium. Metabolism. 2000;49 2 Suppl 1:17-22.
Jennings PE, Belch JJ. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide. Metabolism. 2000;49 2 Suppl 1:23-6.
O’Brien RC, Luo M. The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro. Metabolism. 1997;46 12 Suppl 1:22-5.
Lipinski B. Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complications. 2001;15(4):203-10.
Djordjevic VB, Pavlovic D, Pejovic M, Cvetkovic T, Lecic N, Deljanin-Ilic M. Changes of lipid peroxides and antioxidative factors levels in blood of patients treated with ACE inhibitors. Clin Nephrol. 1997;47(4):243-7.
